Secondary Analysis and Integration of Existing Data to Elucidate Cancer Risk and Related Outcomes (R21 Clinical Trials Not Allowed)
This grant supports researchers in analyzing existing data to understand cancer risk and related outcomes, aiming to address key scientific questions in cancer research.
Funder: National Institutes of Health
Due Dates: June 16, 2025 (New) | July 16, 2025 (Renewal/Resubmission/Revision) | October 16, 2025 (New) | November 16, 2025 (Renewal/Resubmission/Revision) | February 16, 2026 (New) | March 16, 2026 (Renewal/Resubmission/Revision) | June 16, 2026 (New) | July 16, 2026 (Renewal/Resubmission/Revision) | October 16, 2026 (New) | November 16, 2026 (Renewal/Resubmission/Revision) | November 17, 2026 (Final closing/expiration date)
Funding Amounts: Direct costs up to $275,000 over 2 years; no more than $200,000 in any single year.
Summary: Supports secondary analysis and integration of existing data to advance understanding of cancer risk and related outcomes; clinical trials not allowed.
Key Information: Only secondary data analysis (not primary data collection); up to 10% of budget may be used for validation of key findings.
Description
This opportunity, offered by the National Cancer Institute (NCI) and other participating NIH Institutes, supports projects that conduct secondary analysis and integration of existing datasets to elucidate cancer risk and related outcomes. The goal is to leverage clinical, environmental, surveillance, health services, behavioral, lifestyle, genomic, and molecular data to address key scientific questions in cancer research. Innovative approaches to data analysis, new or advanced analytical methods, or integration of multiple datasets are encouraged. The mechanism is the R21 Exploratory/Developmental Research Grant; clinical trials are not permitted.
